ClinicalTrials.gg

Program

GFH276

A development code.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Genfleet Therapeutics (Shanghai).

Furthest: phase 2, since Sep 15, 20253 company-led studies, 3 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfleet Therapeutics (Shanghai)33 open or runningphase 2since Sep 15, 2025Sep 15, 2025Jul 30, 2027phase 2 · NCT07198321

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2025First study: phase 2 study in NeoplasmsFirst studyNCT07198321 · 450 planned · China
  2. Sep 22, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07846358 · 84 planned
  3. Oct 29, 2026Phase 2 study in CRCNCT07915921 · 150 planned

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in NeoplasmsNCT07198321
  2. Dec 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07846358
  3. Apr 30, 2028Primary completion: phase 2 study in CRCNCT07915921

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07915921CRC2Not yet recruitingApr 30, 2028150
NCT07846358Carcinoma, Non-Small-Cell Lung2Not yet recruitingDec 202784
NCT07198321Neoplasms · China2RecruitingJul 30, 2027450

How it is read

Names in the registry

  • “GFH276”, 3 entries

Codes read as this program: GFH276.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.